- Home
- ADAP vs NXC Comparison
ADAP vs NXC Comparison
Compare ADAP & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- NXC
- Stock Information
- Founded
- ADAP 2008
- NXC 1992
- Country
- ADAP United Kingdom
- NXC United States
- Employees
- ADAP N/A
- NXC N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- NXC Investment Managers
- Sector
- ADAP Health Care
- NXC Finance
- Exchange
- ADAP Nasdaq
- NXC Nasdaq
- Market Cap
- ADAP 75.5M
- NXC 83.0M
- IPO Year
- ADAP 2015
- NXC N/A
- Fundamental
- Price
- ADAP $0.08
- NXC $12.95
- Analyst Decision
- ADAP Hold
- NXC
- Analyst Count
- ADAP 6
- NXC 0
- Target Price
- ADAP $1.02
- NXC N/A
- AVG Volume (30 Days)
- ADAP 18.4M
- NXC 17.5K
- Earning Date
- ADAP 08-11-2025
- NXC 01-01-0001
- Dividend Yield
- ADAP N/A
- NXC 3.97%
- EPS Growth
- ADAP N/A
- NXC N/A
- EPS
- ADAP N/A
- NXC 0.19
- Revenue
- ADAP $179,639,000.00
- NXC N/A
- Revenue This Year
- ADAP N/A
- NXC N/A
- Revenue Next Year
- ADAP $38.72
- NXC N/A
- P/E Ratio
- ADAP N/A
- NXC $70.47
- Revenue Growth
- ADAP 878.53
- NXC N/A
- 52 Week Low
- ADAP $0.08
- NXC $11.86
- 52 Week High
- ADAP $1.36
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- ADAP 25.83
- NXC 56.15
- Support Level
- ADAP $0.08
- NXC $12.71
- Resistance Level
- ADAP $0.36
- NXC $12.87
- Average True Range (ATR)
- ADAP 0.02
- NXC 0.11
- MACD
- ADAP -0.02
- NXC -0.00
- Stochastic Oscillator
- ADAP 1.38
- NXC 64.86
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.